Advances in Hematology and Oncology Research(AHOR)

Associate Professor, Department of Pharmacy Practice, ISF College of Pharmacy, India

Publications

• Review Article   
  Olaparib-Induced Mitochondrial Metabolic Collapse Promotes Apoptotic Priming and Overcomes Therapeutic Resistance in CLL
  Author(s): Sonu Kumar*, Sourabh Kosey, Nanak Singh Toor and Khadga Raj Aran
  
  Chronic lymphocytic leukemia (CLL) is a persistent CD5+ B-cell malignancy characterized by clonal expansion of mature B lymphocytes and sustained reliance on prosurvival and mitochondrial metabolic programs. Although Bruton tyrosine kinase inhibitors (BTKI) and BCL2 inhibitors (BCL2i), including ibrutinib and venetoclax, have redefined first- line therapy, CLL remains incurable, with relapse driven by both genomic lesions (e.g., BTK, PLCG2, BCL2 mutations, del(8p), gain2p, amp1q) and non-canonical resistance mechanisms such as oxidative phosphorylation (OXPHOS) re- modelling and altered BCL2–mitochondrial binding dynamics. Ayoub et al., demonstrate that olaparib, a clinically approved PARP inhibitor, sensitizes CLL cells to BTKI and BCL2i through a PARP1-independent mechanism rooted in mitochondrial metabolic collapse rather than DNA damage signalling [1]. Multi-layered bioenerg.. Read More»
  

  Abstract HTML PDF